GlycoMimetics (GLYC) Competitors $0.27 -0.02 (-6.75%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$0.27 +0.00 (+1.79%) As of 01/31/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends GLYC vs. MURA, BYSI, IOBT, OPTN, PRLD, PEPG, VHAQ, KRON, RVPH, and ZIVOShould you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include Mural Oncology (MURA), BeyondSpring (BYSI), IO Biotech (IOBT), OptiNose (OPTN), Prelude Therapeutics (PRLD), PepGen (PEPG), Viveon Health Acquisition (VHAQ), Kronos Bio (KRON), Reviva Pharmaceuticals (RVPH), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry. GlycoMimetics vs. Mural Oncology BeyondSpring IO Biotech OptiNose Prelude Therapeutics PepGen Viveon Health Acquisition Kronos Bio Reviva Pharmaceuticals ZIVO Bioscience GlycoMimetics (NASDAQ:GLYC) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends. Does the media prefer GLYC or MURA? In the previous week, Mural Oncology had 4 more articles in the media than GlycoMimetics. MarketBeat recorded 7 mentions for Mural Oncology and 3 mentions for GlycoMimetics. GlycoMimetics' average media sentiment score of 0.93 beat Mural Oncology's score of 0.10 indicating that GlycoMimetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlycoMimetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mural Oncology 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor GLYC or MURA? GlycoMimetics received 310 more outperform votes than Mural Oncology when rated by MarketBeat users. However, 100.00% of users gave Mural Oncology an outperform vote while only 58.88% of users gave GlycoMimetics an outperform vote. CompanyUnderperformOutperformGlycoMimeticsOutperform Votes31558.88% Underperform Votes22041.12% Mural OncologyOutperform Votes5100.00% Underperform VotesNo Votes Which has preferable earnings and valuation, GLYC or MURA? GlycoMimetics has higher revenue and earnings than Mural Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlycoMimetics$10K1,729.35-$36.90MN/AN/AMural OncologyN/AN/A-$207.45M-$9.14-0.41 Do analysts prefer GLYC or MURA? GlycoMimetics currently has a consensus target price of $8.00, suggesting a potential upside of 2,882.85%. Mural Oncology has a consensus target price of $16.00, suggesting a potential upside of 326.67%. Given GlycoMimetics' higher possible upside, analysts plainly believe GlycoMimetics is more favorable than Mural Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlycoMimetics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Mural Oncology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do insiders and institutionals hold more shares of GLYC or MURA? 75.2% of GlycoMimetics shares are held by institutional investors. Comparatively, 80.2% of Mural Oncology shares are held by institutional investors. 8.7% of GlycoMimetics shares are held by company insiders. Comparatively, 0.1% of Mural Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, GLYC or MURA? GlycoMimetics has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 3.83, meaning that its share price is 283% more volatile than the S&P 500. Is GLYC or MURA more profitable? Mural Oncology's return on equity of -70.10% beat GlycoMimetics' return on equity.Company Net Margins Return on Equity Return on Assets GlycoMimeticsN/A -160.93% -132.85% Mural Oncology N/A -70.10%-61.30% SummaryMural Oncology beats GlycoMimetics on 9 of the 15 factors compared between the two stocks. Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLYC vs. The Competition Export to ExcelMetricGlycoMimeticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.29M$6.85B$5.56B$9.10BDividend YieldN/A2.90%5.32%3.99%P/E RatioN/A9.9790.3018.28Price / Sales1,729.35303.921,249.3080.65Price / CashN/A73.5045.9637.70Price / Book0.455.275.124.70Net Income-$36.90M$136.98M$111.33M$224.47M7 Day Performance-1.51%-0.73%2.32%-0.19%1 Month Performance7.71%0.16%3.17%0.58%1 Year Performance-90.85%7.59%24.57%20.27% GlycoMimetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLYCGlycoMimetics4.1458 of 5 stars$0.27-6.7%$8.00+2,882.8%-90.8%$16.29M$10,000.000.0050News CoverageGap UpMURAMural Oncology3.4508 of 5 stars$3.89-1.6%$16.00+311.6%-15.7%$66.29MN/A-0.43119Short Interest ↑News CoverageBYSIBeyondSpringN/A$1.70-0.9%N/A+79.0%$66.16M$1.75M0.0080News CoverageGap DownIOBTIO Biotech3.7729 of 5 stars$0.98+4.0%$9.33+849.5%-50.0%$64.76MN/A-0.7230Short Interest ↓Positive NewsHigh Trading VolumeOPTNOptiNose4.6117 of 5 stars$6.39-2.4%$16.67+160.8%-68.7%$64.28M$70.99M-1.52190Short Interest ↓Positive NewsGap UpPRLDPrelude Therapeutics3.6616 of 5 stars$1.14-6.2%$4.00+250.9%-66.4%$62.79MN/A-0.64120PEPGPepGen2.6567 of 5 stars$1.89-2.6%$13.67+623.1%-89.6%$62.55MN/A-0.6430Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownVHAQViveon Health AcquisitionN/A$11.00flatN/A-3.1%$62.26MN/A0.002KRONKronos Bio3.6138 of 5 stars$1.03-1.4%$1.63+58.5%-6.5%$61.85M$6.29M-0.72100Short Interest ↑Positive NewsRVPHReviva Pharmaceuticals4.3496 of 5 stars$1.82-5.0%$11.40+528.1%-50.4%$60.69MN/A-1.645Short Interest ↓ZIVOZIVO BioscienceN/A$16.50-12.6%N/A+150.6%$59.73M$30,000.00-3.3810Gap DownHigh Trading Volume Related Companies and Tools Related Companies Mural Oncology Alternatives BeyondSpring Alternatives IO Biotech Alternatives OptiNose Alternatives Prelude Therapeutics Alternatives PepGen Alternatives Viveon Health Acquisition Alternatives Kronos Bio Alternatives Reviva Pharmaceuticals Alternatives ZIVO Bioscience Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLYC) was last updated on 2/2/2025 by MarketBeat.com Staff From Our PartnersStunning Trump Manhattan Project Now UnderwayJust as I predicted, President Trump announced his #1 move during his first 100 days... His allies are call...Banyan Hill Publishing | SponsoredTrump’s New AI Move Could Trigger Massive Melt UPIn his first week in office, President Trump already revoked President Biden's disastrous AI executive order.....InvestorPlace | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredStart Collecting Your $4,243 Monthly Paycheck Next WeekI've just released updated details on a new system for collecting steady dividend income each and every month....Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
